Browse Category

Investment Analysis News 20 December 2025 - 21 December 2025

ASML Holding N.V. Stock (NASDAQ: ASML) Outlook: Latest News, Analyst Forecasts, and Key Risks as of Dec. 20, 2025

ASML Holding N.V. Stock (NASDAQ: ASML) Outlook: Latest News, Analyst Forecasts, and Key Risks as of Dec. 20, 2025

ASML Holding N.V. (NASDAQ: ASML) is ending the week in the spotlight after fresh reporting on China’s workarounds for chipmaking restrictions collided with the bullish “next wave” narrative around High‑NA EUV lithography. ASML’s U.S.-listed shares were last indicated around $1,056,
Chevron Stock (CVX) in Focus After Dec. 20 Venezuela Headlines: What the Latest News, Forecasts, and Analyst Targets Mean for 2026

Chevron Stock (CVX) in Focus After Dec. 20 Venezuela Headlines: What the Latest News, Forecasts, and Analyst Targets Mean for 2026

Chevron Corporation (NYSE: CVX) is heading into the final days of 2025 with its share price hovering around $148—but the most important catalyst for near-term sentiment isn’t an earnings headline or a refinery update. It’s geopolitics: a fast-escalating U.S. crackdown
KLA Corporation Stock (KLAC): Today’s News, Analyst Forecasts, and 2026 Outlook as AI Drives Chip Equipment Spending (Dec. 20, 2025)

KLA Corporation Stock (KLAC): Today’s News, Analyst Forecasts, and 2026 Outlook as AI Drives Chip Equipment Spending (Dec. 20, 2025)

KLA Corporation (NASDAQ: KLAC) heads into the Dec. 20, 2025 weekend with its stock sitting near recent highs after a volatile mid-December stretch that featured a major analyst upgrade, multiple price-target increases, and fresh industry forecasts projecting another leg of
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has
1 70 71 72 73 74 229
Go toTop